Analysis of serum microRNA-122 in a randomized controlled trial of N-acetylcysteine for treatment of antituberculosis drug-induced liver injury.

Muhammed Shiraz Moosa Giusy Russomanno Jeffrey R Dorfman Hannah Gunter Chandni Patel Eithne Costello Daniel F Carr Gary Maartens Munir Pirmohamed Christopher E P Goldring Karen Cohen

Published in: British journal of clinical pharmacology (2023)

miR-122 concentrations in our participants with AT-DILI were considerably higher than previously reported in healthy volunteers and in patients on antituberculosis therapy without liver injury. We did not detect an effect of NAC on miR-122 concentrations. Further research is needed to determine the utility of miR-122 in the diagnosis and management of AT-DILI.

Keyphrases

drug induced
liver injury
cell proliferation
long non coding rna
long noncoding rna
end stage renal disease
newly diagnosed
chronic kidney disease
adverse drug
peritoneal dialysis
emergency department
replacement therapy
patient reported
smoking cessation